Literature DB >> 17136313

Absence of antibody to cyclic citrullinated peptide in sera of non-arthritic patients with chronic hepatitis B virus infection.

Sang-il Lee1, Wan Hee Yoo, Hee Jin Yun, Dal Sik Kim, Hye Soo Lee, Sam Im Choi, Ji An Hur, Yong Gon Cho.   

Abstract

The objective of this study was to investigate if antibody to cyclic citrullinated peptide (anti-CCP) is detected in sera of patients with chronic hepatitis B virus (HBV) infection. Serum anti-CCP and IgA, IgG, and IgM rheumatoid factor (RF) isotypes were measured by enzyme-linked immunosorbent assay on 176 non-arthritic patients with HBV infection. IgA RF, IgG RF, and IgM RF were detectable in 29.5, 21, and 18.8% of the tested sera, respectively, with a total seropositivity rate of 42.7%. Marginally elevated anti-CCP was detected in one patient (0.6%). By regression analysis, there was no statistically significant association between the serum levels of anti-CCP and serum IgA, IgG, or IgM RF (R (2) = 0.033, with respective p values of 0.224, 0.297, and 0.334). In conclusion, anti-CCP was rarely detected in non-arthritic patients with HBV infection in contrast to RF. Thus, testing for anti-CCP may be a useful tool for the diagnosis of rheumatoid arthritis in this population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17136313     DOI: 10.1007/s10067-006-0451-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  16 in total

1.  Chronic seropositive polyarthritis associated with hepatitis B virus-induced chronic liver disease: a sequel of virus persistence.

Authors:  A Csepregi; B Rojkovich; E Nemesánszky; G Poór; M Héjjas; M Horányi
Journal:  Arthritis Rheum       Date:  2000-01

2.  Clinical utility of the anti-CCP assay: experiences with 700 patients.

Authors:  Ulrich Sauerland; Heidemarie Becker; Matthias Seidel; Heiko Schotte; Peter Willeke; Annette Schorat; Bernhard Schlüter; Wolfram Domschke; Markus Gaubitz
Journal:  Ann N Y Acad Sci       Date:  2005-06       Impact factor: 5.691

3.  An investigation on rheumatoid factor of different immunoglobulin classes in hepatitis B virus carriers.

Authors:  K Watanabe; Y Ohkubo; Y Funahashi; T Nishimaki; T Moritoh; R Kasukawa; S Kaise; T Tomita; A Matsukawa
Journal:  Clin Rheumatol       Date:  1991-03       Impact factor: 2.980

Review 4.  Hepatitis C-associated arthritis.

Authors:  D Buskila
Journal:  Curr Opin Rheumatol       Date:  2000-07       Impact factor: 5.006

5.  Arthritis as the main or only symptom of hepatitis B infection.

Authors:  C Pease; A Keat
Journal:  Postgrad Med J       Date:  1985-06       Impact factor: 2.401

6.  Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors.

Authors:  S Bas; T V Perneger; M Seitz; J-M Tiercy; P Roux-Lombard; P A Guerne
Journal:  Rheumatology (Oxford)       Date:  2002-07       Impact factor: 7.580

7.  Interferon therapy is effective in treatment of hepatitis B-induced polyarthritis.

Authors:  L J Scully; P Karayiannis; H C Thomas
Journal:  Dig Dis Sci       Date:  1992-11       Impact factor: 3.199

8.  Clinical utility of the anti-CCP assay in patients with rheumatic diseases.

Authors:  D M Lee; P H Schur
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

9.  Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis.

Authors:  I Vallbracht; J Rieber; M Oppermann; F Förger; U Siebert; K Helmke
Journal:  Ann Rheum Dis       Date:  2004-09       Impact factor: 19.103

10.  Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement.

Authors:  Michele Bombardieri; Cristiano Alessandri; Giancarlo Labbadia; Cristina Iannuccelli; Francesco Carlucci; Valeria Riccieri; Vincenzo Paoletti; Guido Valesini
Journal:  Arthritis Res Ther       Date:  2004-01-29       Impact factor: 5.156

View more
  10 in total

1.  Anti-cyclic citrullinated peptide and rheumatoid factor in HIV positive patients.

Authors:  Zeljko Romic; Lovorka Derek; Vitomir Burek; Adriana Unic; Tihana Serdar; Domagoj Marijancevic; Jadranka Morovic-Vergles; Josko Mitrovic; Mladen Petrovecki
Journal:  Rheumatol Int       Date:  2010-05-27       Impact factor: 2.631

Review 2.  Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis.

Authors:  Rohit Aggarwal; Katherine Liao; Raj Nair; Sarah Ringold; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2009-11-15

Review 3.  Antibodies against cyclic citrullinated peptides in infectious diseases--a systematic review.

Authors:  Isabella Lima; Mittermayer Santiago
Journal:  Clin Rheumatol       Date:  2010-08-05       Impact factor: 2.980

4.  Anti-cyclic citrullinated peptide and rheumatoid factor in patients with chronic hepatitis B and hepatitis B carriers.

Authors:  Ediz Dalkılıç; Mustafa Ferhat Öksüz; Ayşe Nur Tufan; Aysun Özbek; Ali Nizamoğlu; Mürside Esra Dolarslan; Belkıs Nihan Coşkun; Yavuz Pehlivan
Journal:  Eur J Rheumatol       Date:  2015-03-31

5.  IgG RF and anti-CCP2 antibody can be positive in undifferentiated arthritis due to streptococcal infection, hepatitis B virus, tuberculosis, trauma and hypothyroidism: a preliminary study.

Authors:  Usha Singh; Pamod Kumar Verma; Priyanka Bhagat; Sangeeta Singh; Suman Singh; Nand Kumar Singh
Journal:  Rheumatol Int       Date:  2011-07-26       Impact factor: 2.631

6.  The diagnostic utilities of anti-agalactosyl IgG antibodies, anti-cyclic citrullinated peptide antibodies, and rheumatoid factors in rheumatoid arthritis.

Authors:  Hee Jung Ryu; Fujio Takeuchi; Shoji Kuwata; Yoon Jun Kim; Eun Young Lee; Eun Bong Lee; Yeong Wook Song
Journal:  Rheumatol Int       Date:  2009-12-15       Impact factor: 2.631

Review 7.  Hepatitis B virus (HBV) and autoimmune disease.

Authors:  Ram Maya; M Eric Gershwin; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

Review 8.  The role of anti-cyclic cytrullinate antibodies testing in rheumatoid arthritis.

Authors:  Cristiano Alessandri; Roberta Priori; Mariagrazia Modesti; Riccardo Mancini; Guido Valesini
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

9.  The positivity of rheumatoid factor and anti-cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection.

Authors:  E Orge; A Cefle; Ayten Yazici; N Gürel-Polat; S Hulagu
Journal:  Rheumatol Int       Date:  2009-06-23       Impact factor: 2.631

10.  Chronic hepatitis C virus infection is associated with the development of rheumatoid arthritis: a nationwide population-based study in taiwan.

Authors:  Fu-Hsiung Su; Chien-Sheng Wu; Fung-Chang Sung; Shih-Ni Chang; Chien-Tien Su; Ying-Hua Shieh; Chih-Ching Yeh
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.